The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
|Articles|July 19, 2022
Daily Medication Pearl: Dalbavancin (Dalvance)
Author(s)Saro Arakelians, PharmD
Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms.
Advertisement
Medication Pearl of the Day: Dalvance (dalbavancin)
Indication: Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.
Insight:
- Dosing: Two-dose regimen 1000 mg followed 1 week later by 500 mg.
- Dosage forms: For injection 500 mg of lyophilized powder in a single-use vial for reconstitution.
- Adverse events: The most common adverse reactions in patients treated with dalbavancin were nausea (5.5%), headache (4.7%), and diarrhea.
- Mechanism of action: Dalbavancin, a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking.
Source:
Advertisement
Related to this article
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
Pharmacists make a difference in patients’ lives through MTM services.
The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.
Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.
Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
Advertisement
Advertisement
Trending on Pharmacy Times
1
VYD2311 May Offer Vaccine-Hesitant and Immunocompromised Individuals a New COVID-19 Immunization Option
2
National Pharmacy Technician Day: Celebrating the Backbone of Pharmacy
3
Cemdisiran’s Potential to Reduce Hospitalizations in Myasthenia Gravis
4
Pneumonic Plague: What Pharmacists Need to Know About Treatment
5